Mineralys Therapeutics, Inc.MLYSNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank80
3Y CAGR+75.6%
5Y CAGR+125.2%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+75.6%/yr
Annual compound
5Y CAGR
+125.2%/yr
Recent deceleration
Percentile
P80
Within normal range
vs 5Y Ago
58x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$170.58M-11.3%
2024$192.40M+127.3%
2023$84.66M+168.9%
2022$31.48M+68.1%
2021$18.73M+536.3%
2020$2.94M-